Symbols

MENS

Jyong Biotech·NASDAQ

--(--)

7.45 / 10

Outperform

Analyst coverage is absent, but fund‑flow rating is good (7.45). Overall inflow ratio is 45.2% with a negative trend, while small and large investors show positive inflows (52% and 53.9%). Medium and extra‑large investors are net outflows, suggesting mixed sentiment.

Fund Flow Rating

What is the analyst consensus for MENS?

MENS holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.45/10 (Outperform).